List of works - Patrick Mcgrath

A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial

scientific article published on 15 August 2018

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

scientific article

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

scientific article

A genomewide association study of citalopram response in major depressive disorder

scientific article

A mega-analysis of genome-wide association studies for major depressive disorder

scientific article

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

scientific article published on July 2012

Abnormal functional brain asymmetry in depression: evidence of biologic commonality between major depression and dysthymia

scientific article

Acceptability of second-step treatments to depressed outpatients: a STAR*D report

scientific article published on 01 May 2007

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

scientific article (publication date: November 2006)

Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample

scientific article

Antidepressants normalize the default mode network in patients with dysthymia.

scientific article published on April 2013

Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome

scientific article

Association of Whole-Genome and NETRIN1 Signaling Pathway–Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank

scholarly article by Miruna C. Barbu et al published July 2018 in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder

scientific article

Atypical depression: current status and relevance to melancholia.

scientific article published on January 2007

Can People With Nonsevere Major Depression Benefit From Antidepressant Medication?

scientific article published on December 27, 2011

Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report

scientific article published in April 2009

Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report

scientific article published on 01 May 2007

Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome

scientific article

DSM-IV depression with atypical features: is it valid?

scientific article published on 02 September 2009

Do atypical features affect outcome in depressed outpatients treated with citalopram?

scientific article

Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes

scientific article

Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial

Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial

scientific article published in October 2011

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

scientific article

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression

scientific article published on 26 April 2018

Is duloxetine effective treatment for depression with atypical features?

scientific article

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

scientific article

Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D.

scientific article published on 5 February 2008

Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder

scientific article published on 27 August 2008

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

scientific article

Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features

article

Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report

scientific article

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

scientific article

Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort

article

The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients

scientific article published on 17 January 2019

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

scientific article

Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.

scientific article

Variants in PDE11A and PDE1A are not associated with citalopram response

scientific article published in December 2007

List of works by Patrick Mcgrath

A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

A genomewide association study of citalopram response in major depressive disorder

A mega-analysis of genome-wide association studies for major depressive disorder

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

Abnormal functional brain asymmetry in depression: evidence of biologic commonality between major depression and dysthymia

Acceptability of second-step treatments to depressed outpatients: a STAR*D report

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample

Antidepressants normalize the default mode network in patients with dysthymia.

Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome

Association of Whole-Genome and NETRIN1 Signaling Pathway–Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder

Atypical depression: current status and relevance to melancholia.

Can People With Nonsevere Major Depression Benefit From Antidepressant Medication?

Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report

Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report

Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome

DSM-IV depression with atypical features: is it valid?

Do atypical features affect outcome in depressed outpatients treated with citalopram?

Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes

Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial

Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression

Is duloxetine effective treatment for depression with atypical features?

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D.

Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features

Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort

The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.

Variants in PDE11A and PDE1A are not associated with citalopram response